Christina Carlander
About me
Senior Consultant of Infectious Diseases, sub-specialized in HIV care, at the Department of Infectious Diseases, Karolinska University Hospital.
Assocate professor (docent in Swedish) and Group leader at the Department of Medicine Huddinge. Also affiliated to the Department of Medical Epidemiology and Biostatistics at KI, Solna.
Since 2021, I am the Director (registerhållare in Swedish) of the National Quality Register of HIV (InfCareHIV).
Research
My research is focused on register-based studies, mainly studying comorbidity in people living with HIV. Through linking of the Swedish National HIV Register InfCareHIV with other nationwide demographic and health registers we collect population-based data on an individual level to study time-trends, prediction-models, mortality rates and risk factors of comorbidity in people living with and without HIV. Read more about current projects here and at the webpages for SANCA and COSMOHS.
Articles
- Journal article: AIDS. 2026;40(11):1681-1689Timiryasova A; Greenberg L; Domingo P; Tarr PE; Egle A; Martin C; Mussini C; Wit F; Cingolani A; Lehmann C; Castagna A; Petoumenos K; Sabin CA; Borges A; El-Sadr W; Lundgren J; Hosein S; Carlander C; Amstutz A; Grabmeier-Pfistershammer K; Garges H; Marongui A; Young LA; Peters L; Ryom L
- Article: AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV. 2026;:1-13Lalloo EC; Brannstrom J; Mehdiyar M; Carlander C; Mellgren A
- Journal article: BMC INFECTIOUS DISEASES. 2026;26(1):1835Sorstedt E; Nilsson S; Sonnerborg A; Carlander C; Treutiger CJ; Mansson F; Anghagen L; Berggren H; Gisslen M; Yilmaz A
- Article: HIV MEDICINE. 2026Smith K; Locke M; Andersson E; Broddesson S; Carlander C; Yilmaz A; Albert J; Leitner T; Brannstrom J
- Article: BMJ OPEN. 2026;16(9):e108693Nilsson J; Deng Y; Elvstam O; Killander-Moller I; Lei J; Mansson F; Naucler P; Nygren J; Ruhe-van der Werff S; Wagner P; Yilmaz A; Brannstrom J; Boman M; Carlander C
- Article: AIDS. 2026;40(9):1346-1354Pantazis N; Sabin C; Costagliola D; Grabar S; Carlander C; Gill J; van Sighem A; Jarrin I; Meyer L; Ruiz-Burga E; Tariq S; Spire B; Burns F; Touloumi G
- Journal article: OPEN FORUM INFECTIOUS DISEASES. 2026;13(8):ofag490Surial B; Neesgaard B; Chammartin F; Ryom L; Petoumenos K; Reekie J; Paredes R; Zangerle R; Smith C; Martin C; Wit F; Jaschinski N; Mussini C; Monforte AD; Castagna A; Carlander C; Hetman L; Sohani E; Lehmann C; Hosein SR; Van Wyk JA; Bissio E; Lundgren J; Rauch A; Gunthard HF; Wandeler G; Greenberg L
- Article: CLINICAL INFECTIOUS DISEASES. 2026;82(6):e1252-e1261Killander Moller I; Wagner P; Brannstrom J; Backdahl T; Elvstam O; Gisslen M; Hedberg P; Mellgren A; Mansson F; Naucler P; Nilsson J; Nowak P; Sparen P; Eliasson B; Carlander C
- Article: HIV MEDICINE. 2026;27(6):945-958Falk S; Nilsson J; Moller IK; Elvstam O; Wagner P; Mellgren A; Mansson F; Carlander C; Brannstrom J
- Article: JAMA NETWORK OPEN. 2026;9(6):e2620512Meglic E; Ploner A; Deng Y; Brannstrom J; Elvstam O; Mansson F; Mellgren A; Lei J; Carlander C
- Article: JOURNAL OF THE INTERNATIONAL AIDS SOCIETY. 2026;29(3):e70054Sorstedt E; Nduva G; Mansson F; Mellgren A; Repits J; Fernvik E; Stubbs A; Schroeder M; Brannstrom J; Carlander C
- Article: JAMA ONCOLOGY. 2026;12(2):177-184Deng Y; Wu S; Ask LS; Lepp T; Clements M; Milerad H; Carlander C; Lei J
- Article: ECLINICALMEDICINE. 2026;91:103739Han WM; Neesgaard B; Knappik M; Cavassini M; Abela IA; Timiryasova A; Greenberg L; Martin C; Mussini C; Wit F; Sabin C; Castagna A; Abutidze A; El-Sadr W; Bonnet F; Sarcletti M; Carlander C; Hachfeld A; Weis N; Vannappagari V; Rogatto FP; Young LA; Hosein SR; Ryom L; Petoumenos K
- Article: CANCERS. 2025;17(24):4000Timiryasova A; Greenberg L; Domingo P; Tarr PE; Egle A; Martin C; Mussini C; Wit F; Cingolani A; Lehmann C; Castagna A; Petoumenos K; Sabin CA; Bonnet F; Lundgren J; Bottanelli M; Hosein S; Carlander C; Amstutz A; Grabmeier-Pfistershammer K; Garges H; Marongiu A; Young LA; Peters L; Ryom L
- Article: OPEN FORUM INFECTIOUS DISEASES. 2025;12(10):ofaf586Jaschinski N; Neesgaard B; Wit F; Van der Valk M; Kowalska J; Ridolfo AL; Gunthard HF; Stockle M; Wallner E; Nowak P; Castagna A; D'arminio Monforte A; Petoumenos K; Hoy JF; Hosein S; Lundgren J; Garges H; Rogatto F; Young L; Peters L; Mocroft A; Ryom L; RESPOND SG
- Article: VACCINE. 2025;62:127580Moller IK; Hedberg P; Wagner P; Sparen P; Gisslen M; Naucler P; Aleman S; Bergman P; Carlander C
- Article: BLOOD ADVANCES. 2025;9(13):3170-3181Hedberg P; Blixt L; Sylvan SE; Moller IK; Lindahl H; Kahn F; Nilsdotter-Augustinsson A; Fredrikson M; Nystrom S; Bergman P; Carlander C; Aleman S; Osterborg P; Osterborg A; Hansson L
- Article: HIV MEDICINE. 2025;26(8):1311-1316Nilsson J; Elvstam O; Sorstedt E; Wagner P; Nowak P; Brannstrom J; Carlander C
- Article: OPEN FORUM INFECTIOUS DISEASES. 2025;12(4):ofaf110Baeckdahl T; Hedberg P; Vesterbacka J; Carlander C; Sonnerborg A; Nowak P
- Article: LAKARTIDNINGEN. 2025;122:24097Carlander C; Borgfeldt C; Hammarstedt Nordenvall L
- Show more
All other publications
- Letter: CLINICAL INFECTIOUS DISEASES. 2026;:e1059-e1060Killander Moller I; Brannstrom J; Elvstam O; Gisslen M; Mellgren A; Mansson F; Naucler P; Nowak P; Eliasson B; Carlander C
- Corrigendum: VACCINE. 2025;67:127855Moller IK; Hedberg P; Wagner P; Sparen P; Gisslen M; Naucler P; Aleman S; Bergman P; Carlander C
- Conference publication: HIV MEDICINE. 2025;26:117-119Falk S; Nilsson J; Moller IK; Elvstam O; Wagner P; Mellgren A; Mansson F; Carlander C; Brannstrom J
- Conference publication: HIV MEDICINE. 2025;26:717-721Moller IK; Wagner P; Backdahl T; Hedberg P; Nowak P; Sparen P; Gisslen M; Naucler P; Mellgren A; Mansson F; Brannstrom J; Elvstam O; Eliasson B; Carlander C
- Conference publication: HIV MEDICINE. 2025;26:58-60Moller IK; Rehnman G; Hedberg P; Wagner P; Sparen P; Gisslen M; Naucler P; Aleman S; Bergman P; Carlander C
- Conference publication: HIV MEDICINE. 2025;26:216-217Burns F; Stamoulopoulos A; Pantazis N; Sabin C; Costagliola D; Meyer L; Pulido F; Van Sighem A; Carlander C; Gill J; Wittkop L; Anne AV; Tariq S; Touloumi G
- Conference publication: HIV MEDICINE. 2025;26:217-218Pantazis N; Van der Valk M; Costagliola D; Sabin C; Grabar S; van Sighem A; Meyer L; Anne AV; Jarrin I; Carlander C; Gill J; Spire B; Tariq S; Burns F; Touloumi G
- Conference publication: VALUE IN HEALTH. 2024;27(12)Sorstedt E; Nduva G; Hiltunen S; Repits J; Mansson F; Mellgren A; Fernvik E; Stubbs A; Schroeder M; Brannstrom J; Carlander C
- Conference publication: JOURNAL OF THE INTERNATIONAL AIDS SOCIETY. 2024;27:273-275Timiryasova A; Greenberg L; Domingo P; Tarr PE; Egle A; Martin C; Mussini C; Wit F; Cingolani A; Vehreschild JJ; Castagna A; Petoumenos K; Sabin C; El-Sadr W; Bonnet F; Lundgren J; Botanelli M; Hosein S; Carlander C; Amstutz A; Grabmeier-Pfistershammer K; Garges H; Marongiu A; Young LA; Peters L; Ryom L
- Preprint: SSRN ELECTRONIC JOURNAL. 2024Blixt L; Hedberg P; Carlander C; Granath F; Bergman P; Aleman S; Hansson L; Fredriksson OBOTCSG
- Preprint: MEDRXIV. 2023Karakosta A; Ruiz-Burga E; Tariq S; Touloumi G; Nicholls EJ; Pantazis N; Jarrin I; Van der Valk M; Sabin C; Mussini C; Meyer L; Anne AV; Carlander C; Grabar S; Wittkop L; Spire B; Gill J; Porter K; Burns F; Collaboration C
- Conference publication: HIV MEDICINE. 2023;24:686-688Moller IK; Hedberg P; Sparen P; Gisslen M; Naucler P; Carlander C
- Conference publication: HIV MEDICINE. 2023;24:696-697Nilsson J; Elvstam O; Sorstedt E; Nowak P; Brannstrom J; Carlander C
- Letter: JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2023;94(3):e5-e8Stenberg E; Carlander C; Cao Y; Ottosson J; Naeslund E
- Conference publication: HIV MEDICINE. 2019;20:195-196Carlander C; Wagner P; Sparen P; Svedhem V
- Doctoral thesis: 2018Carlander C
- Letter: BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY. 2017;124(11):1795Carlander C
Grants
- Swedish Research Council1 December 2025 - 30 November 2028There is no cure of HIV infection due to latent intact HIV in cellular reservoirs, mainly in resting CD4+ cells. Several latency reversing agents (LRA) have been identified but no reduction in the reservoirs has been achieved in vivo. We screened a CRISPR-CAS knockout library targeting 2.000 drugable human genes and identified several novel genes maintaining HIV latency including C-terminal Src kinase (CSK). When inhibiting CSK, reactivation of latent HIV was seen in vitro. We will now further investigate the therapeutic potential of novel LRAs using state-of-the-art model systems. Our plan includes i) CRISPR-CAS screening for more druggable targets that reverse latency in GKO reporter virus infected Jurkat and primary human T cellsii) identification of novel LRAs aand testing of small molecule inhibitors, including the CSK inhibitoriii) testing selected LRAs on primary CD4+ T-cells from patients with suppressive viremia, assessing the reactivation of the replication competent reservoir and iv) in a subset of patients correlate variations in the reactivation potential to the integration sites in eu- or heterochromatin of the proviral HIV DNA. Our novel assays and approaches in HIV latency research will facilitate the identification for novel efficient LRAs and open new pathways towards functional HIV cure.
- Swedish Research Council1 January 2025 - 31 December 2028Anal cancer incidence is rising globally. The International Anal Neoplasia Society recommends screening high-risk individuals using high-resolution anoscopy (HRA). However, most countries lack anal cancer screening guidelines, and HRA's limited availability necessitates more efficient risk stratification methods. This project aims to advance anal cancer prevention through comprehensive register-based research and innovative biomarker discovery, with a particular focus on women, an understudied population in anal cancer research. Our objectives are toI) quantify Sweden's anal cancer burden, stratifying by immune status to identify risk groups, II) evaluate the feasibility, cost-effectiveness, and acceptability of implementing international anal cancer screening guidelines for women with HIV, III) investigate DNA methylation markers' predictive potential for precancerous anal lesion progression, and IV) assess circulating HPV DNA in plasma as a pre-diagnostic biomarker for anal cancer. We will utilize national registers and international collaborations throughI) a nationwide register-based cohort study of anal cancer burden, II) a prospective register-based study of anal cancer screening in women with HIV, III) analysis of DNA methylation markers in anal samples, and IV) an international register-based nested case-control study of circulating HPV DNA. This project will generate crucial knowledge to inform evidence-based anal cancer prevention policies for high-risk groups.
- Swedish Research Council1 January 2025 - 31 December 2028Despite an increased risk of cancer in people with HIV, the only current HIV specific cancer screening guideline is for cervical-cancer-screening, to which our research-group has earlier contributed. Clearly, there is a need for HIV specific screening guidelines for other cancersbreast, lung, anal, and colon cancer, where an increased risk, earlier debut, or poorer prognosis among people with HIV has been identified. The aim of this project is to firstly develop predictive models for cancer risk in people with HIV, using unsupervised machine learning techniques on datasets based on demographic, socioeconomic, HIV-related, and comorbidity factors. Secondly, we aim to evaluate these prediction models through counterfactual prediction to justify the development of a clinical user-friendly tool to help guide individualized cancer prevention and screening for the population with HIV. To our knowledge this is the first project using machinelearning to create cancer-prediction models in an HIV-population. In summary, our aim is to create a clinical tool "HIVigilant: Cancer Screening Guide”, for individualized cancer prevention and screening of the population with HIV. This clinical tool can be integrated in the HIV register for easy access and use for all HIV clinicians in Sweden. This will save lives and reduce the burden of cancer among people with HIV. The knowledge that this project contributes can also be useful in the work of cancer prevention in the general population.
- Swedish Research Council1 January 2025 - 31 December 2028Despite an increased risk of cancer in people with HIV, the only current HIV specific cancer-screening guideline is for cervical-cancer-screening, to which our research-group has earlier contributed. Clearly, there is a need for HIV specific screening guidelines for other cancersbreast, lung, anal, and colon cancer, where an increased risk, earlier debut, or poorer prognosis among people with HIV has been identified. The aim of this project is to firstly develop predictive models for cancer risk in people with HIV, using unsupervised machine learning techniques on datasets based on demographic, socioeconomic, HIV-related, and comorbidity factors. Secondly, we aim to evaluate these prediction models through counterfactual prediction to justify the development of a clinical user-friendly tool to help guide individualized cancer prevention and screening for the population with HIV. To our knowledge this is the first project using machine-learning to create cancer-prediction models in an HIV-population. In summary, our aim is to create a clinical tool "HIVigilant: Cancer Screening Guide”, for individualized cancer prevention and screening of the population with HIV. This clinical tool can be integrated in the HIV register for easy access and use for all HIV clinicians in Sweden. This will save lives and reduce the burden of cancer among people with HIV. The knowledge that this project contributes can also be useful in the work of cancer prevention in the general population.
- Swedish Research Council1 December 2024 - 30 November 2028Anal cancer incidence is rising globally. The International Anal Neoplasia Society recommends screening high-risk individuals using high-resolution anoscopy (HRA). However, most countries lack anal cancer screening guidelines, and HRA´s limited availability necessitates more efficient risk stratification methods. This project aims to advance anal cancer prevention through comprehensive register-based research and innovative biomarker discovery, with a particular focus on women, an understudied population in anal cancer research. Our objectives are toI) quantify Sweden´s anal cancer burden, stratifying by immune status to identify risk groups, II) evaluate the feasibility, cost-effectiveness, and acceptability of implementing international anal cancer screening guidelines for women with HIV, III) investigate DNA methylation markers´ predictive potential for precancerous anal lesion progression, and IV) assess circulating HPV DNA in plasma as a pre-diagnostic biomarker for anal cancer. We will utilize national registers and international collaborations throughI) a nationwide register-based cohort study of anal cancer burden, II) a prospective register-based study of anal cancer screening in women with HIV, III) analysis of DNA methylation markers in anal samples, and IV) an international register-based nested case-control study of circulating HPV DNA. This project will generate crucial knowledge to inform evidence-based anal cancer prevention policies for high-risk groups.
- Comorbidity in people with HIVThe Gilead Sciences Nordic Fellowship, unrestricted1 January 2023 - 1 January 2025
- Immunological non-response despite viral suppression-incidence and risk factorsSwedish Doctors against AIDS Research foundation1 January 2022 - 1 January 2025
- Swedish Research Council1 June 2021 - 31 May 2025
- Risk of severe COVID-19 in people living with HIVThe Gilead Sciences Nordic Fellowship, unrestricted1 January 2020 - 1 January 2023
- Employment status of people living with and without HIV in SwedenSwedish Doctors against AIDS Research foundation1 January 2019 - 1 January 2021
Employments
- Adjunct Lecturer, Department of Medicine, Huddinge, Karolinska Institutet, 2024-2027
- Adjunct Lecturer, Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, 2024-2027
Degrees and Education
- Associate professor, Infectious Diseases, Medicine Huddinge, Karolinska Institutet, 2024
- Degree Of Doctor Of Philosophy, Department of Medicine, Huddinge, Karolinska Institutet, 2019